drugset
drugset / Trial / NCT05653713

Effects of CSL324 in the Lung After Segmental Challenge

NCT05653713 ↗

Phase 1 Completed 40 enrolled CSL Behring
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This is a phase 1b, randomized, double-blind, placebo-controlled study in healthy volunteers to investigate the antiinflammatory effect of pretreatment with CSL324 on response to a lipopolysaccharide (LPS) endotoxin challenge in a single lung segment. Saline will be instilled into a segment in the contralateral lung for the purpose of comparison.

Timeline

Start
2022-12-20
Primary completion
2023-07-21
Completion
2023-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Anumigilimab Monoclonal antibody — Intravenous

Indications

No indication recorded.